CN107232182A - A kind of mesenchymal stem cells MSCs cell cryopreservation agent - Google Patents
A kind of mesenchymal stem cells MSCs cell cryopreservation agent Download PDFInfo
- Publication number
- CN107232182A CN107232182A CN201710528049.8A CN201710528049A CN107232182A CN 107232182 A CN107232182 A CN 107232182A CN 201710528049 A CN201710528049 A CN 201710528049A CN 107232182 A CN107232182 A CN 107232182A
- Authority
- CN
- China
- Prior art keywords
- cell
- mscs
- polypeptide
- cells
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a kind of mesenchymal stem cells MSCs cell cryopreservation agent, it contains 0.2%w/v sucrose, 0.5%w/v low-density lipoproteins, 3%w/v trehalose, 2%w/v lecithin, polypeptide 100ppmw/v, bFGF 1.5%w/v, vitamin E 1%w/v, glycerine 5%v/v are finally with DMEM culture mediums and hyclone according to 1:1 ratio is settled to 100ml.Agent is frozen in the cell of the present invention; glycerine and trehalose and vitamin E and polypeptide, which have, clearly resists damage of the external injury to cell; polypeptide also has damage of the ice crystal to cell when protecting cells from freezing, and remaining several component is necessary for maintaining the existence of specific MSCs cells.The cell cryopreservation agent that the present invention is provided is used to freeze culture cell, in particular improves the survival rate after freeze-stored cell recovery.With preferable application prospect.
Description
Technical field
The present invention relates to histocyte culture technique field, and in particular to a kind of mesenchymal stem cells MSCs cell freezes
Deposit agent and its preparation method and application.
Background technology
In marrow except containing can differentiation and development into various haemocytes candidate stem cell in addition to, also containing producing non-hematopoiesis group
The mescenchymal stem cell (MSCs) knitted, because it is easier adherent and forms fibroblast-like clone, therefore the document having also
MSC, referred to as attached cell (fibroblastic colony units-forming (CFU-F).Due to their support structures from marrow, and
And can as trophoderm hematopoiesis support stem cell growth, therefore also someone is called marrow stromal cell.
There is MSCs multi-lineage potential to be verified by internal and external test.Friedenstem first confirmed that MSG,
With the ability for being divided into bone, cartilage, fibr tissue.Pittenger in 1999 etc. is separated from the ilium sample of bone marrow of people
MSCs has been arrived, in vitro under the induction of different differentiation conditions, Gegenbaur's cell, cartilage cell or fat cell can be formed, and
The later cell of clone has similar differentiation characteristic, and it is pluripotent stem cell fully to prove bone marrow MSCs.But,
Pittenger et al. experiment can not still confirm the MSG being separated to, whether be Committed progenitor cells mixture, in marrow whether
Really there is the single stem cell with multi-lineage potential.Halleu etc. by the mesenchymal cell being separated to dilute after with low close
Degree inoculation, the clone as a result grown by individual cells can continuous amplification cultivation generation more than 20, and can be divided into skeletonization in vitro
Cell, chondroblast, lipoblast, do thin so as to confirm and contain to have in the mesenchymal cell separated in marrow
Born of the same parents' characteristic is the individual cells of height self-renewal capacity and polyphyly differentiation potential.Anita etc. is by using marrow stromal cell
Clone's culture, the human bone marrow substrate cell clone of analysis 185 non-infinite propagation is divided into skeletonization, into cartilage, into fatty thin
The ability of born of the same parents, it was confirmed that MSCs vitro differentiation model:The cell that these three cell lines can be divided into is the mesenchyma ancestral of early stage
Cell, the orderly loss of its differentiation potential causes the direction of differentiation to gradually reduce.On MSG, the report of multipotency over nearly 20 years
Road is a lot, and this kind of in vitro study experiment is to employ a variety of derivants for different differentiation directions, and MSCs is made respectively
Break up to different thesocytes such as skeletonization, into cartilage, into fat, sarcoblast.
MSCs has convenient material drawing, and culture in vitro can keep its multi-lineage potential, and genetic background is stable, implants
It is preferable seed cell in organizational project without immunological rejection, it is easy to the features such as clinical practice.Although multidirectional point of MSCs
Changing potential is widely confirmed, but its in vivo studies is only limitted to be repaired the tissue of itself with toy MSCs and lacked
Damage.In order to which MSCs is used for into big animal and the primate close with the mankind, Fu Wenyu etc. notes people's bone marrow MSCs of culture
Enter nude mice by subcutaneous, after one month injection site observed people MSCs differentiation bone, cartilage, fat, skeletal muscle, tendon forceps sample group
The Various Tissues type such as knit.Tippi etc. establishes people's tire sheep model of allogene, by people MSG, is implanted in tire sheep, it was observed that
People MSCs was survived in tire sheep up to 13 months, and site specific be divided into fat, cartilage, myocyte etc., further
MSCs still has polyphyly differentiation potential after confirming transplanting, it was further observed that in the damage location of people's tire sheep model, MSCs points of people
The cell concentration increase of change, thus it is speculated that be probably implantation MSCs be induced to expand and participate under this damaging conditions tissue repair or
Person's regenerative response.The research is those the ostosis defects that can be just diagnosed in uterus, the disease such as muscular dystrophy
Clinical treatment is laid a good foundation.
MSCs is easier to separate from the marrow of patient, in vitro after many times of amplifications, carries out a variety of purposes
Operation, then again defeated time in patient body, freezing is standby the need for the cell for preparing therebetween is inevitable.At present, do
The frozen stock solution that cell cryopreservation is used has two classes containing serum and serum-free, and because serum has, complicated component, quality be unstable, valency
The shortcomings of lattice are expensive, serum-free freezes turns into development trend with resuscitation technique.Cord blood stem cell relies primarily on anti frozen liquid two
The protection of methyl sulfoxide (DMSO) and serum.Commonly used cell-protecting also has HES 0ES), polyethylene glycol (PEG)
Deng.But, DMSO can produce toxic action to cell, and irreversible damage is caused to the stem cell frozen.To obtain source side
Just MSCs stem cells, it is the urgent demand in this area to carry out effective MSCs stem cell cryopreservings method, sets up a kind of long-term low
Temperature preserves the method for MSCs stem cells for promoting grinding for MSCs stem cells to make internal disorder or usurp and using being significant.
The content of the invention
The technical problem to be solved in the present invention is to provide a kind of mesenchymal stem cells MSCs cell cryopreservation agent and accordingly
Preparation method and application method.
Technical scheme is as follows：
A kind of mesenchymal stem cells MSCs cell cryopreservation agent, it is characterised in that be made up of following each component：0.2%w/v sugarcanes
Sugar, 0.5%w/v low-density lipoproteins, 3%w/v trehalose, 2%w/v lecithin, polypeptide 100ppm w/v, bFGF 1.5%
W/v, vitamin E 1%w/v, glycerine 5%v/v are finally with DMEM culture mediums and hyclone according to 1:1 ratio is settled to
100ml, the sequence such as SEQ ID NO of the polypeptide：Shown in 1-2 is any.The polypeptide is directed to by inventor by specificity
The substantial amounts of library immunoscreening for the early stage that MSCs cells are carried out is obtained, and the polypeptide, which has, protects MSCs cells from the work(of damage
Energy.Its title is respectively MSCs-1 (SEKTWFVWYSWRKQGCIEDSRPTYHYC), MSCs-2
(KAREWEPDRHMTHWIPGFHHMGCSYH)。
In the frozen stock solution of the cell of the present invention, glycerine and trehalose and vitamin E and polypeptide, which have, clearly to be resisted
Damage of the external injury to cell, particularly polypeptide, the also damage with ice crystal when protecting cells from freezing to cell, its
Component is necessary for maintaining the existence of specific MSCs cells in complementary set.
Present invention also offers a kind of preparation method of the frozen stock solution of cell, will each component mixing shake up.
Present invention also offers a kind of mesenchymal stem cells MSCs cryopreservation methods, comprise the following steps:
A. prepared by frozen stock solution:Described cells frozen storing liquid is prepared, by each component according to conventional operating method by each component
It can be obtained according to the mixing of corresponding ratio；
B. prepared by cell suspension:Culture grows into one bottle of the MSCs cells of individual layer, and 0.25% trypsin solution digests 4 points
Clock, abandons trypsin solution, adds DMEM nutrient solution 15ml, and gently being blown and beaten with suction pipe makes cell uniform, centrifuges 4000 revs/min, abandons supernatant,
Step A frozen stock solution 2ml are added, is mixed, inserts in sterile cryopreservation tube；
C. freeze:Cryopreservation tube is first frozen into 30min at 4 DEG C, -30 DEG C is then placed in and freezes lh, -80 DEG C is placed into and freezes
3h, finally moves into liquid nitrogen and preserves；
D. cell recovery:Take out cryopreservation tube and be quickly placed into 37 DEG C of water-baths, concussion is melted completely up to cell suspension, Ran Houyong
5 times of DMEM liquid dilutions, 1000r/min centrifugation 5min, centrifugation removes supernatant, repeated 3 times.The cell suspended concentration is
108Cell/ml-1010Cell/ml.
Beneficial effects of the present invention:
The cells frozen storing liquid of the present invention, recovery cell survival rate relatively uses regular growth frozen stock solution up to more than 98.5%
Recovery survival rate be obviously improved, there is no the loss of cell.
The MSCs stem cell cryopreserving liquids of the present invention can preserve MSCs stem cells for a long time, and cytoactive does not change, and protect
Activity of cell biology is demonstrate,proved.
Nerve cell cryopreservation methods of the present invention, operation is simple and feasible, affordable, with preferable practical value.
Embodiment
Embodiment 1
It is separately added into 0.2%w/v sucrose, 0.5%w/v low-density lipoproteins, 3%w/v trehalose, 2%w/v lecithins
Fat, polypeptide 100ppm w/v, bFGF 1.5%w/v, vitamin E 1%w/v, glycerine 5%v/v finally use DMEM culture mediums and tire
Cow's serum is according to 1:1 ratio is settled to 100ml.The wherein sequence of polypeptide such as SEKTWFVWYSWRKQGCIEDSRPTYHYC institutes
Show.
Embodiment 2
It is separately added into 0.2%w/v sucrose, 0.5%w/v low-density lipoproteins, 3%w/v trehalose, 2%w/v lecithins
Fat, polypeptide 100ppm w/v, bFGF 1.5%w/v, vitamin E 1%w/v, glycerine 5%v/v finally use DMEM culture mediums and tire
Cow's serum is according to 1:1 ratio is settled to 100ml.The wherein sequence of polypeptide such as KAREWEPDRHMTHWIPGFHHMGCSYH institutes
Show.
Comparative Example I
70ml MEM cell culture fluids, 20ml calf serum, I0ml dimethyl sulfoxide (DMSO) is measured respectively, is mixed to prepare
Regular growth frozen stock solution.
Comparative Example I I
By dimethyl sulfoxide (DMSO) 5%w/v, 0.5%w/v low-density lipoproteins, 1%w/v trehalose, 1%w/v lecithin,
BFGF 1%w/v, vitamin E 1%w/v, finally with DMEM culture mediums and hyclone according to 1:1 ratio is settled to
100ml。
Comparative Example I II
By dimethyl sulfoxide (DMSO) 5%w/v, 0.5%w/v low-density lipoproteins, 1%w/v trehalose, 1%w/v lecithin,
Polypeptide 1%w/v, bFGF 1%w/v, vitamin E 1%w/v, finally with DMEM culture mediums and hyclone according to 1:1 ratio
It is settled to 100ml.
The compliance test result of the frozen stock solution of embodiment 3
Cells frozen storing liquid prepared by above example 1-2 and Comparative Example I-III, carries out cell by the following method respectively
Freeze and recovering experiment.
Cell cryopreservation process:
Culture grows into the human leukemia stem cell of individual layer, its cell density about 6*109Individual/ml, adds pH7.0 PBS
Wash cell surface once.
Cell is digested 4 minutes with 0.25% trypsin solution, trypsin solution is abandoned, DMEM nutrient solution 15ml is added, uses suction pipe
Gently piping and druming makes cell uniform, centrifuges 4000 revs/min, abandons supernatant, adds embodiment 1-3 and the frozen stock solution prepared by comparative example 1
2ml, is mixed, and inserts in sterile cryopreservation tube；
Freezing:Cryopreservation tube is first frozen into 30min at 4 DEG C, -30 DEG C is then placed in and freezes lh, -80 DEG C is placed into and freezes
3h, finally moves into liquid nitrogen and preserves；Freeze respectively 1 week, 4 months, 8 months.Every group of 3 repetitions.
Cell recovery:Take out cryopreservation tube and be quickly placed into 37 DEG C of water-baths, concussion until cell suspension melts completely, then with 5
Times DMEM liquid dilution, 1000r/min centrifugation 5min, centrifugation removes supernatant, repeated 3 times, calculates cell survival rate.As a result such as
Under：
The freeze-stored cell of 8 months is taken, cell differentiation culture is carried out, wherein described MSCs cells can be normally carried out point
Change, differentiation efficiency reaches 95.3%, and Comparative Example I-III takes out cell its differentiation rate can only achieve 58.4%, 60.2%,
80.5%, this sufficiently illustrates that cytoactive receives very big influence.
The specific detection of embodiment 4
By the culture medium of embodiment 1, respectively for other several stem cells：Candidate stem cell, NSC, fat is dry
Cell carries out carrying out refrigeration test using the training method of embodiment 3, freezes experiment by 8 months, it is found that after 8 months
This several cell survival rate be between 80%-90% survival rate, illustrate, refrigerant of the invention can be with specific
Cultivate MSCs.
Above-described embodiment is not limited for the present invention preferably embodiment, but embodiments of the present invention by embodiment
System, other any Spirit Essences and the change made under principle, modifications without departing from the present invention, combines, substitutes, simplifying and should be
Equivalence replacement mode, is included within protection scope of the present invention.
Sequence table
The ＞ Chen Yin of ＜ 110 are put down
A kind of mesenchymal stem cells MSCs cell cryopreservation agent of the ＞ of ＜ 120
〈160〉2
〈210〉1
〈211〉27
〈212〉PRT
The ＞ artificial sequences of ＜ 213
〈400〉MSCs-1
SEKTWFVWYSWRKQGCIEDSRPTYHYC
〈211〉26
〈212〉PRT
The ＞ artificial sequences of ＜ 213
〈400〉MSCs-2
KAREWEPDRHMTHWIPGFHHMGCSYH
Claims (4)
1. a kind of cell cryopreservation agent, it is characterised in that:It can specific protection MSCs.
2. a kind of cell cryopreservation agent, is made up of following each component：0.2% w/v sucrose, 0.5% w/v low-density lipoproteins, 3%
W/v trehalose, 2% w/v lecithin, polypeptide 100ppm w/v, bFGF 1.5% w/v, the w/v of vitamin E 1%, glycerine 5%
V/v is finally with DMEM culture mediums and hyclone according to 1:1 ratio is settled to 100ml, the sequence such as SEQ ID of the polypeptide
NO：Shown in 1-2 is any.
3. the preparation method of the cells frozen storing liquid described in claim any one of 1-2, it is characterised in that including mixing the formula
The component of ratio, obtains described freezing agent.
4. the cells frozen storing liquid described in claim any one of 1-2 is deposited after raising freezes mesenchymal stem cells MSCs cell recovery
Application in motility rate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710528049.8A CN107232182A (en) | 2017-06-30 | 2017-06-30 | A kind of mesenchymal stem cells MSCs cell cryopreservation agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710528049.8A CN107232182A (en) | 2017-06-30 | 2017-06-30 | A kind of mesenchymal stem cells MSCs cell cryopreservation agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107232182A true CN107232182A (en) | 2017-10-10 |
Family
ID=59990814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710528049.8A Pending CN107232182A (en) | 2017-06-30 | 2017-06-30 | A kind of mesenchymal stem cells MSCs cell cryopreservation agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107232182A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108378019A (en) * | 2018-03-13 | 2018-08-10 | 洛阳轩智生物科技有限公司 | A kind of frozen stock solution of people's stem spermatogonium |
| CN109744227A (en) * | 2018-12-28 | 2019-05-14 | 广州益养生物科技有限公司 | A kind of cells frozen storing liquid and its application |
| CN112167246A (en) * | 2020-10-31 | 2021-01-05 | 郑州贝贝生物科技有限公司 | Dental pulp mesenchymal stem cell cryopreservation liquid and cryopreservation method |
| CN112167243A (en) * | 2020-10-14 | 2021-01-05 | 中国科学技术大学 | Erythrocyte cryopreservation liquid and rapid cryopreservation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105394029A (en) * | 2016-01-05 | 2016-03-16 | 潘时辉 | Cell cryopreservation liquid used for treatment of leukemia |
| CN105394026A (en) * | 2015-10-31 | 2016-03-16 | 江苏赛尔特生物技术有限公司 | New method for cryopreserving hematopoietic stem cells |
| CN105432599A (en) * | 2016-01-04 | 2016-03-30 | 潘时辉 | Cell freezing medium for treating leukemia |
| CN105454222A (en) * | 2016-02-02 | 2016-04-06 | 河南省银丰生物工程技术有限公司 | Cell cryopreservation liquid and preparation method and application thereof |
| CN105494317A (en) * | 2016-03-06 | 2016-04-20 | 李倩 | Cell freezing medium for human adipose-deprived stem cells |
-
2017
- 2017-06-30 CN CN201710528049.8A patent/CN107232182A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105394026A (en) * | 2015-10-31 | 2016-03-16 | 江苏赛尔特生物技术有限公司 | New method for cryopreserving hematopoietic stem cells |
| CN105432599A (en) * | 2016-01-04 | 2016-03-30 | 潘时辉 | Cell freezing medium for treating leukemia |
| CN105394029A (en) * | 2016-01-05 | 2016-03-16 | 潘时辉 | Cell cryopreservation liquid used for treatment of leukemia |
| CN105454222A (en) * | 2016-02-02 | 2016-04-06 | 河南省银丰生物工程技术有限公司 | Cell cryopreservation liquid and preparation method and application thereof |
| CN105494317A (en) * | 2016-03-06 | 2016-04-20 | 李倩 | Cell freezing medium for human adipose-deprived stem cells |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108378019A (en) * | 2018-03-13 | 2018-08-10 | 洛阳轩智生物科技有限公司 | A kind of frozen stock solution of people's stem spermatogonium |
| CN108378019B (en) * | 2018-03-13 | 2021-03-02 | 诺赛联合(北京)生物医学科技有限公司 | Cryopreservation liquid for human spermatogonial stem cells |
| CN109744227A (en) * | 2018-12-28 | 2019-05-14 | 广州益养生物科技有限公司 | A kind of cells frozen storing liquid and its application |
| CN112167243A (en) * | 2020-10-14 | 2021-01-05 | 中国科学技术大学 | Erythrocyte cryopreservation liquid and rapid cryopreservation method |
| CN112167246A (en) * | 2020-10-31 | 2021-01-05 | 郑州贝贝生物科技有限公司 | Dental pulp mesenchymal stem cell cryopreservation liquid and cryopreservation method |
| CN112167246B (en) * | 2020-10-31 | 2021-07-27 | 北京泰盛生物科技有限公司 | Dental pulp mesenchymal stem cell cryopreservation liquid and cryopreservation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103396990B (en) | Method for preparing mesenchymal stem cells | |
| CN104770363B (en) | A kind of frozen stock solution of mescenchymal stem cell and cryopreservation methods | |
| CN101974484B (en) | Method for preparing human umbilical cord mesenchymal stem cells | |
| CN107232182A (en) | A kind of mesenchymal stem cells MSCs cell cryopreservation agent | |
| CN103251649B (en) | The preparation method of human mesenchymal stem cell culture supernatant freeze-dried powder | |
| CN107384857B (en) | Culture method of autologous adipose-derived mesenchymal stem cells and culture medium used in culture method | |
| CN105238750B (en) | A kind of method of recovery umbilical cord mesenchymal stem cells | |
| CN105229145A (en) | The manufacture method of sheet cell culture | |
| CN106421920B (en) | A kind of fat filler and preparation method thereof | |
| CN104974984A (en) | Adipose tissue-derived mesenchymal stem cell amplification culture method | |
| CN104857022A (en) | MSC (mesenchymal stem cell) injection as well as preparation and application thereof | |
| CN104542576A (en) | Frozen stock solution of neural stem cells and application method of frozen stock solution | |
| CN106465710A (en) | Fatty tissue frozen stock solution and fatty tissue cryopreservation methods | |
| CN109234229A (en) | Method and digestive enzyme compositions used from placenta blood vessel separating mesenchymal stem cell | |
| CN106359368A (en) | Cell cryoprotectant and cryopreservation method | |
| CN106978396A (en) | A kind of amplification cultivation method of fat mesenchymal stem cell clone | |
| CN102965337A (en) | Method for separating and extracting human subcutaneous adipose-derived mesenchymal stem cells and special culture medium for extraction | |
| CN113201489A (en) | Preparation method of adipose-derived mesenchymal stem cell working cell bank | |
| CN104862271A (en) | Simple limbal stem cell separating and in-vitro culture kit and method | |
| CN105596372A (en) | Method for treating various severe skin damages by using autogeneic bone marrow-derived mesenchymal stem cells (BMSCs) | |
| CN103060269A (en) | Method for extracting and cultivating mesenchymal stem cells | |
| CN106701682A (en) | Method for separating hematopoietic stem cells from umbilical cord blood and amplifying CD34 positive cells | |
| CN105456293A (en) | Stem cell-based medicinal product for treating diabetes and preparing method thereof | |
| CN109628388A (en) | With digestive enzyme compositions from placenta blood vessel separating mesenchymal stem cell | |
| CN106417253A (en) | Cryopreservation liquid and method for skeletal muscle stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |
|
| RJ01 | Rejection of invention patent application after publication |